.png){kind=icon}
Return
Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathies
.png){kind=icon}
OA
AI
DOI：10.1016/j.omtn.2023.102084.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Overexpression of SNCA has been implicated in the pathogen-esis of synucleinopathies, particularly Parkinson's disease (PD) and dementia with Lewy bodies (DLB). While PD and DLB share some clinical and pathological similarities, each disease presents distinct characteristics, including the primary affected brain region and neuronal type. We aimed to develop neuronal-type-specific SNCA-targeted epigenome therapies for synucleinopathies. The system is based on an all-in-one len-tiviral vector comprised of CRISPR-dSaCas9 and guide RNA (gRNA) targeted at SNCA intron 1 fused with a synthetic repressor molecule of Kruppel-associated box (KRAB)/ methyl CpG binding protein 2 (MeCp2) transcription repression domain (TRD). To achieve neuronal-type specificity for dopa-minergic and cholinergic neurons, the system was driven tyrosine hydroxylase (TH) and choline acetyltransferase (ChAT) promoters, respectively. Delivering the system into hu-man induced pluripotent stem cell (hiPSC)-derived dopami-nergic and cholinergic neurons from a patient with the SNCA triplication resulted in efficient and neuronal-type-specific downregulation of SNCA-mRNA and protein. Furthermore, the reduction in SNCA levels by the gRNA-dSaCas9-repressor system rescued disease-related cellular phenotypes including Ser129-phophorylated a-synuclein, neuronal viability, and mitochondrial dysfunction. We established a novel neuronal-type-specific SNCA-targeted epigenome therapy and provided in vitro proof of concept using human-based disease models. Our results support the therapeutic potential of our system for PD and DLB and provide the foundation for further pre-clinical studies in animal models toward investigational new drug (IND) enablement and clinical trials.
Keywords:
GENOME-WIDE ASSOCIATION
LEWY BODY PATHOLOGY
ALPHA-SYNUCLEIN
PARKINSONS-DISEASE
ALZHEIMERS-DISEASE
GENETIC-ANALYSIS
COMMON VARIANTS
BASAL FOREBRAIN
MESSENGER-RNA
STEM-CELLS
Journal
M
IF:
6.1
Papers:
1.4K
Citations:
1.4W
Organization
Cited Papers
Radicicol, an Hsp90 inhibitor, inhibits intestinal inflammation and leakage in abdominal sepsis
PREAI
ShareSaveShareSaveParkinson's disease, dementia with Lewy bodies and multiple system atrophy are α-synucleinopathies
PREAI
ShareSaveShareSaveShareSaveShareSavePurification and Immobilization of Superoxide Dismutase Obtained from Saccharomyces cerevisiae TBRC657 on Bacterial Cellulose and its Protective Effect against Oxidative Damage in Fibroblasts.png)
Biomolecules
OAAI
BiomoleculesIF0
OAAIShareSaveSulfate reduction with electrons directly derived from electrodes in bioelectrochemical systems
PREAI
ShareSave
View more